• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Update: Annual Changes to the Nasdaq-100® Index

    12/12/23 6:00:00 PM ET
    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Investment Bankers/Brokers/Service
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NDAQ alert in real time by email

    NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023.

    The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same.

    Information

    For information about the company being added to the Nasdaq-100 Index® per this update, please visit the company website: Take-Two Interactive Software, Inc. – https://www.take2games.com/.

    About Nasdaq Global Indexes

    Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Nasdaq Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic, and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index, and design solutions to financial organizations worldwide.

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

    The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The Nasdaq OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    - NDAQG -

    Media Relations ContactsInvestor Relations Contact  
    Name: Camille StaffordName: Index Client Services  
    Email: [email protected]

    Email  [email protected]  
      
    Name: Jennifer Lawson 
    Email: [email protected] 
      


    Primary Logo

    Get the next $NDAQ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NDAQ
    $PFE
    $SGEN
    $TTWO

    CompanyDatePrice TargetRatingAnalyst
    Take-Two Interactive Software Inc.
    $TTWO
    7/28/2025$265.00Overweight
    Wells Fargo
    Nasdaq Inc.
    $NDAQ
    7/25/2025$115.00Neutral → Buy
    UBS
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    Nasdaq Inc.
    $NDAQ
    4/17/2025$91.00Neutral → Buy
    Redburn Atlantic
    Nasdaq Inc.
    $NDAQ
    4/8/2025$74.00Overweight → Equal-Weight
    Morgan Stanley
    Take-Two Interactive Software Inc.
    $TTWO
    2/19/2025$250.00Buy
    DA Davidson
    Take-Two Interactive Software Inc.
    $TTWO
    1/27/2025$175.00 → $230.00Buy → Neutral
    UBS
    Take-Two Interactive Software Inc.
    $TTWO
    1/27/2025$175.00 → $230.00Neutral → Buy
    UBS
    More analyst ratings

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    SEC Filings

    View All

    SEC Form S-8 filed by Take-Two Interactive Software Inc.

    S-8 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Filer)

    9/26/25 4:29:41 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form S-8 filed by Take-Two Interactive Software Inc.

    S-8 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Filer)

    9/26/25 4:25:41 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Take-Two Interactive Software Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Filer)

    9/19/25 4:30:18 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Take-Two with a new price target

    Wells Fargo initiated coverage of Take-Two with a rating of Overweight and set a new price target of $265.00

    7/28/25 9:00:36 AM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    NASDAQ upgraded by UBS with a new price target

    UBS upgraded NASDAQ from Neutral to Buy and set a new price target of $115.00

    7/25/25 8:52:40 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Cantor Fitzgerald initiated coverage on Pfizer with a new price target

    Cantor Fitzgerald initiated coverage of Pfizer with a rating of Neutral and set a new price target of $24.00

    4/22/25 8:03:45 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zollar Alfred W bought $203,970 worth of shares (2,542 units at $80.24), increasing direct ownership by 5% to 49,293 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    11/14/24 4:29:16 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    10/31/24 4:06:54 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

    Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T

    9/30/25 12:45:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasdaq to Hold Third Quarter 2025 Investor Conference Call

    NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ: NDAQ) has scheduled its third quarter 2025 financial results announcement.   Who:Nasdaq's CEO, CFO, and additional members of its senior management team  What:Review Nasdaq's third quarter 2025 financial results  When:Tuesday, October 21, 2025 Results Call: 8:00 AM ET   Senior management will be available for questions from the investment community following prepared remarks. All participants can access the conference via webcast through the Nasdaq Investor Relations website at http://ir.nasdaq.com/. Note: The press release and results presentation for the third quarter 2025 results will be posted on the Nasdaq Investor Relatio

    9/29/25 4:15:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Hearing Against Pfizer Set For 29 September In Contraceptive 'Depo-Provera' Multidistrict Litigation Overseen By Levin Papantonio

    The number of lawsuits filed has tripled to over 1300 since May New US peer-reviewed study adds to body of research confirming link between use of Depo-Provera and increased risk of brain tumours Global pharmaceutical company Pfizer Inc. (NYSE: PFE), manufacturer of contraceptive injection Depo-Provera (DMPA), is facing a multidistrict litigation (MDL No. 3140) in the USA being brought on behalf of women who developed an intracranial meningioma, a type of brain tumour after using Pfizer's Depo-Provera. This litigation followed a study by EPI-PHARE (Roland et al.) published in March 2024 in the British Medical Journal, which found that women who had used the Pfizer contraceptive inje

    9/25/25 3:37:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chairman & CEO Bourla Albert

    4 - PFIZER INC (0000078003) (Issuer)

    9/17/25 6:09:28 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Siminoff Ellen F sold $101,948 worth of shares (414 units at $246.25) (SEC Form 4)

    4 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Issuer)

    9/16/25 4:12:40 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Chief Financial Officer Goldstein Lainie sold $2,500,000 worth of shares (10,000 units at $250.00), decreasing direct ownership by 4% to 274,078 units (SEC Form 4)

    4 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Issuer)

    9/9/25 4:14:56 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Financials

    Live finance-specific insights

    View All

    Nasdaq to Hold Third Quarter 2025 Investor Conference Call

    NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ: NDAQ) has scheduled its third quarter 2025 financial results announcement.   Who:Nasdaq's CEO, CFO, and additional members of its senior management team  What:Review Nasdaq's third quarter 2025 financial results  When:Tuesday, October 21, 2025 Results Call: 8:00 AM ET   Senior management will be available for questions from the investment community following prepared remarks. All participants can access the conference via webcast through the Nasdaq Investor Relations website at http://ir.nasdaq.com/. Note: The press release and results presentation for the third quarter 2025 results will be posted on the Nasdaq Investor Relatio

    9/29/25 4:15:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 4, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Third Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the confer

    9/23/25 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

    Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer's pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an initial enterprise value of $4.9 billion with a CVR of up to $22.50 per share in additional payments Pfizer to host a public webcast at 8 am EDT today Pfizer Inc. (NYSE:PFE) and Metsera, Inc. (NASDAQ:MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a

    9/22/25 6:45:00 AM ET
    $MTSR
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Leadership Updates

    Live Leadership Updates

    View All

    Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

    Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T

    9/30/25 12:45:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Puro.earth Secures €11 M Series B Financing Led by Nasdaq with Participation from Fortum Innovation & Venturing to strengthen its supplier infrastructure

    HELSINKI, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Puro.earth, a leading carbon-crediting platform for engineered carbon dioxide removal (CDR), today announced it has raised €11 million in a Series B funding round led by Nasdaq with participation from Fortum Innovation & Venturing. Puro.earth will deploy this funding to strengthen the infrastructure that supports its best-in-class certification journey for suppliers. Key initiatives include enabling more frequent issuance of high-integrity carbon removal credits, facilitating offtake agreements, and advancing open integration of digital measurement, reporting, and verification (dMRV) tools. The new investment builds on a period of strong gr

    9/4/25 7:00:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Mafia: The Old Country Now Available Worldwide

    Dive into the roots of organized crime in 1900s Sicily with a compelling new cast of characters today Today, 2K and Hangar 13 announced that Mafia: The Old Country, the highly anticipated latest installment in the acclaimed Mafia franchise, is now available worldwide for PlayStation®5 (PS5®), Xbox Series X|S, and PC via Steam. The story will take players back in time to 1900s Sicily, which has been painstakingly created with the utmost authenticity and detail. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250808972468/en/Today, 2K and Hangar 13 announced that Mafia: The Old Country, the highly anticipated latest installment i

    8/8/25 10:00:00 AM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/12/24 3:53:01 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G filed by Nasdaq Inc.

    SC 13G - NASDAQ, INC. (0001120193) (Subject)

    11/8/24 10:52:39 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/4/24 1:18:47 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance